Birgitte Sogaard
Valby, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
NeuroPharm study: EEG wakefulness regulation as a biomarker in MDD.
Journal: Journal of psychiatric research
Published: September 14, 2020
Pretreatment qEEG biomarkers for predicting pharmacological treatment outcome in major depressive disorder: Independent validation from the NeuroPharm study.
Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
Published: July 29, 2020
Optimizing Behavioral Paradigms to Facilitate Development of New Treatments for Anhedonia and Reward Processing Deficits in Schizophrenia and Major Depressive Disorder: Study Protocol.
Journal: Frontiers in psychiatry
Published: March 04, 2020
Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy.
Journal: British journal of clinical pharmacology
Published: May 12, 2015
Postprandial prolactin suppression appears absent in antipsychotic-treated male patients.
Journal: Psychoneuroendocrinology
Published: March 25, 2015
Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients.
Journal: The Journal of clinical psychiatry
Published: October 03, 2013
The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers.
Journal: Basic & clinical pharmacology & toxicology
Published: February 02, 2012
Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects.
Journal: Basic & clinical pharmacology & toxicology
Published: October 12, 2011
Showing 1-8 of 8
Last Updated: 09/26/2026